18F-FDG PET/CT: Brain Imaging

  • April-Louise SmithEmail author
  • Anna Barnes
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


18F-2-Fluoro-2-deoxyglucose (18F-FDG) can be used to image regional cerebral glucose consumption which allows diagnostic imaging for a number of neurological indications such as dementia, epilepsy and movement disorders. Although not often used in neuro-oncology, it remains the method of choice in the diagnosis and staging of CNS lymphoma. Adhering to guidelines for patient preparation, using the correct imaging acquisition and reconstruction parameters, as well as defining the optimal image display for reporting are all crucial in order to obtain images of diagnostic quality. Furthermore, reporting images in the presence of neurological degenerative diseases can benefit hugely using additional post-processing and quantification of the images. This chapter summarises published guidelines, at the time of writing, on optimal imaging procedures for brain 18F-FDG PET/CT and introduces the reader to some of the more widely available quantification tools and references for optional further reading of developments in the field.


  1. 1.
    Purandare NC, Puranik A, Shah S. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation? Nucl Med Commun. 2017;38(12):1109–16.PubMedGoogle Scholar
  2. 2.
    Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014;12(3):148–57. Epub 2014 Mar 11PubMedGoogle Scholar
  3. 3.
    Varrone A, Asenbaum S, Borght TV, Booij J, Nobili F, Nagren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103–10.PubMedGoogle Scholar
  4. 4.
    Waxman AD, Herholz K, Lewis DH, Herscovitch P, Minoshima S, Ichise M, et al. Society of nuclear medicine procedure guideline for FDG PET brain imaging. v1. Society of nuclear medicine molecular imaging. 2009.Google Scholar
  5. 5.
    Sarikaya I. PET studies in epilepsy. Am J Nucl Med Mol Imaging. 2015;5(5):416–30.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidlines for tumour PET imaging. v1. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200.PubMedGoogle Scholar
  7. 7.
    Leiderman DB, Albert P. The dynamics of metabolic change followingseizures as measured by positron emission tomography with fludeoxyglucose F 18. Arch Neurol. 1994;51(9):932–6.PubMedGoogle Scholar
  8. 8.
    Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. UK: Public Health England; March 2018.Google Scholar
  9. 9.
    Lassmann M, Biassoni L, Monsieurs M, Franzius C, EANM Dosimetry and Paediatrics Committees. The new EANM paediatric dosage card: additional notes with respect to F-18. Eur J Nucl Med Mol Imaging. 2008;35(9):1666–8.PubMedGoogle Scholar
  10. 10.
    Tong S, Alessio AM, Kinahan PE. Image reconstruction for PET/CT scanners: past achievements and future challenges. Imaging Med. 2010;2(5):529–45.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Dickson JC, O’Meara C, Barnes A. A comparison of CT- and MR-based attenuation correction in neurological PET. Eur J Nucl Med Mol Imaging. 2014;41(6):1176–89.Google Scholar
  12. 12.
    Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. NeuroImage. 2009;45(4):1241–52.PubMedGoogle Scholar
  13. 13.
    Manda PK, Mahajan R, Dinovc ID. Structural brain atlases: design, rationale, and applications in normal and pathological cohorts. J Alzheimers Dis. 2012;31:169–88.Google Scholar
  14. 14.
    Brett M, Johnsrude IS, Owen AM. The problem of functional localization in the human brain. Nat Rev Neurosci. 2002;3:243–9.PubMedGoogle Scholar
  15. 15.
    Mazziotta JC, Toga AW. A probabilistic atlas of the human brain: theory and rationale for its development: the international consortium for brain mapping (ICBM). NeuroImage. 1995;2:89–101.PubMedGoogle Scholar
  16. 16.
    Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994;35(9):1528–37.PubMedGoogle Scholar
  17. 17.
    Minoshima S, Kuhl DE, Foster NL, Koeppe RA, Frey KA. A diagnostic approach in alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238–48.Google Scholar
  18. 18.
    Borghammer P, Aanerud J, Gjedde A. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. NeuroImage. 2009;46(4):981–8.PubMedGoogle Scholar
  19. 19.
    Shen X, Liu H, Hu H, Shi P. The relationship between cerebral glucose metabolism and age: report of a large brain PET data set. PLoS One. 2012;7(12):e51517.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Groeschel S, Vollmer B, King M, Connelly A. Developmental changes in cerebral grey and white matter volume from infancy to adulthood. Int J Dev Neurosci. 2010;28(6):481–9.PubMedGoogle Scholar
  21. 21.
    Van Bogaert P, Wikler D, Damhaut P, Szliwowski H, Goldman S. Regional changes in glucose metabolism during brain development from the age of 6 years. NeuroImage. 1998;8(1):62–8.PubMedGoogle Scholar
  22. 22.
    Kinnala A, Suhonen-Polvi H, Aärimaa T, Kero P, Korvenranta H, Ruotsalainen U, et al. Cerebral metabolic rate for glucose during the first six months of life: an FDG positron emission tomography study. Arch Dis Child Fetal Neonatal Ed. 1996;74(3):153–7.Google Scholar
  23. 23.
    De Blasi B, Barnes A, Galazzo IB, Hua C, Shulkin B, Koepp M, et al. Age-specific 18F-FDG image processing pipelines and analysis are essential for individual mapping of seizure foci in paediatric patients with intractable epilepsy. J Nucl Med. 2018; Scholar
  24. 24.
    Schenk V. Scenium v.1 and PET, white paper paper. USA: Siemens, Medical Solutions; 2006.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Institute of Nuclear MedicineUniversity College London Hospital NHS Foundation TrustLondonUK

Personalised recommendations